Semaglutide

What it is: A GLP-1 receptor agonist — the active ingredient in Ozempic, Wegovy, and Rybelsus. It slows gastric emptying and signals fullness to the brain.

What it does: Most users see 10-15% body weight reduction over several months, alongside dramatically reduced appetite, less 'food noise,' improved insulin sensitivity, and lower cardiovascular risk markers.

How it's used: Once-weekly subcutaneous injection, titrated up gradually from 0.25 mg over 4-12 weeks to a maintenance dose of 1-2.4 mg.